Welcome, this website is intended for international healthcare professionals with an interest in the treatment of Advanced Prostate Cancer. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program

Clinical Genitourinary Cancer, In Press, Corrected Proof, Available online 23 June 2016, Available online 23 June 2016


Therapeutic options for metastatic castration-resistant prostate cancer have considerably changed in the past decade. In this retrospective analysis of patients included in the Swiss Enzalutamide Named Patent Program, we analyzed the outcome of patients based on different sequencing strategies reflecting current daily practice. We demonstrate a median overall survival of more than 3 years and different effects in regard to treatment sequences.



Enzalutamide is a second-generation androgen receptor (AR) inhibitor that binds to and blocks the AR with higher affinity than previously available AR inhibitors. High activity has been proven in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and in chemotherapy-naive patients with mCRPC. However, its activity in patients previously treated with other novel agents (for example, abiraterone and/or cabazitaxel), remains controversial.

Patients and Methods

The aim of this retrospective analysis of the Swiss Enzalutamide Named Patient Program was to evaluate clinical efficacy and safety of enzalutamide treatment in patients with mCRPC progressing after docetaxel and other lines of therapy considering different treatment sequences. We report on 44 patients treated with enzalutamide.


The median survival time from diagnosis of CPRC was 41.1 months (95% confidence interval [CI], 32.3-49.8 months). Enzalutamide was used as a second, third, fourth, fifth, sixth, or seventh-line therapy in 13%, 20%, 31%, 20%, 11%, and 2% of patients. The median duration of enzalutamide treatment was 3.0 months (range, 1-21 months). Median progression-free survival was 3.0 months (95% CI, 2.4-3.7 months). The estimated median overall survival was 6.3 months (95% CI, 4.6-8.1 months). Sixteen patients (36.4%) had a prostate-specific antigen decrease of ≥ 30%, and 11 patients (25.0%) of ≥ 50%, respectively. In multivariate analysis, the absence of previous therapy with abiraterone and a prostate-specific antigen response of ≥ 50% on enzalutamide therapy were significantly associated with overall survival on enzalutamide treatment.


Our results show that enzalutamide has modest activity in extensively pretreated patients. However, there is a subgroup of patients achieving benefit from enzalutamide therapy even after pretreatment with abiraterone.

Keywords: Abiraterone, Androgen receptor antagonist, Antihormonal drugs, PSA, Treatment sequence.


1 Department of Medical Oncology, University Hospital Basel, Basel, Switzerland

2 Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

3 Department of Medical Oncology, University Hospital Lausanne, CHUV, Lausanne, Switzerland

4 Department of Medical Oncology, Cantonal Hospital Chur, Chur, Switzerland

5 Department of Medical Oncology, Cantonal Hospital St Gallen, St Gallen, Switzerland

6 Medical Oncology Practice, Biel, Switzerland

7 Department of Medical Oncology, Cantonal Hospital Luzern, Luzern, Switzerland

8 Department of Medical Oncology, Bürgerspital Solothurn, Solothurn, Switzerland

9 Department of Medical Oncology, Cantonal Hospital Olten, Olten, Switzerland

10 Department of Medical Oncology, Cantonal Hospital Aarau, Aarau, Switzerland

11 Department of Medical Oncology, Triemlispital Zürich, Zürich, Switzerland

12 Onkologie Länggasse, Bern, Switzerland

13 Medical Oncology Practice, Winterthur, Switzerland

14 Department of Medical Oncology, Waidspital Zürich, Zürich, Switzerland

Address for correspondence: Sacha I. Rothschild, MD, PhD, University Hospital Basel, Medical Oncology, Petersgraben 4, 4031 Basel, Switzerland

F.S. and S.R. contributed equally to this work as last authors.